ArticleInternational journal of ophthalmology2025
Visual and functional outcomes of a new diffractive trifocal intraocular lens with smooth micro phase technology in patients undergoing cataract surgery.
Article in International journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Safety and Efficacy of Eyevisc™ 2.4% Ophthalmic Viscosurgical Device in Cataract Surgery.Cureus · 2026Article
- A One-Year Visual and Safety Evaluation of a Newly Available Trifocal Intraocular Lens in Patients With Bilateral Cataracts: Clinical Outcomes From a Prospective Study.Journal of ophthalmology · 2026Article
Corrections and comments
- Erratum issuedCORRIGENDUM.2026
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo assess the refractive and functional outcomes of a novel trifocal intraocular lens (IOL) with smooth micro phase technology.
methodsThis prospective, single-arm, single-center, observational study included patients who underwent cataract surgery with the implantation of the AT ELANA 841P (Carl Zeiss Meditec, Berlin, Germany) IOL. Visual acuity (VA) at distance, intermediate, and near were evaluated 1- and 3-month postop as well as refractive outcomes. Monocular and binocular defocus curve, binocular contrast sensitivity (M&S® Technologies) and patient satisfaction with the Catquest-9SF questionnaire were measured at 3-month postop.
resultsIn total, 46 eyes (23 patients) were bilaterally implanted with the IOL. Mean patient age was 59.86±5.55y. At 1-month postop, monocular corrected VA for distance, intermediate, and near were -0.15±0.09, 0.11±0.10, and 0.15±0.12 logMAR, respectively. These outcomes remained stable at the 3-month follow-up (
conclusionThe AT ELANA 841P IOL offers excellent visual outcomes across distance, intermediate, and near ranges, along with satisfactory contrast sensitivity. Additionally, the lens is associated with high patient satisfaction and minimal visual difficulties during daily activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.